Literature DB >> 22256939

Lessons learned from 20 years of newborn screening for cystic fibrosis.

R John H Massie1, Lisette Curnow, Judith Glazner, David S Armstrong, Ivan Francis.   

Abstract

OBJECTIVE: To compare three cystic fibrosis (CF) newborn screening strategies used in Victoria since 1989. DESIGN, SETTING AND PARTICIPANTS: Retrospective review of newborn screening and clinical records for people with CF born in Victoria between 1989 and 2008 to compare screening strategies: repeat immunoreactive trypsinogen (IRT) testing (IRT/IRT, 1989-1990), IRT and p.F508del mutation analysis (IRT/p.F508del, 1991-2006) and IRT with analysis of 12 CFTR mutations (IRT/12 mutations, 2007-2008). MAIN OUTCOME MEASURES: Total number of infants screened, people identified with CF (by screening or clinical diagnosis), number of CF-affected terminations of pregnancy, and number of carriers detected.
RESULTS: There were 420 people born with CF (live-birth prevalence, 1/3139; 95% CI, 1/2853-1/3462) and 78 CF-affected pregnancy terminations (overall prevalence, 1/2647; 95% CI, 1/2425-1/2896). Of the babies born with CF, 283 (67.4%) were detected by newborn screening alone, 61 (14.5%) had meconium ileus, 33 (7.9%) had a family history of CF, nine (2.1%) were diagnosed antenatally, and 34 (8.1%) were missed by screening (17 missed because IRT level was < 99th percentile, two with repeat IRT level not elevated, 14 without a screened CFTR mutation, and one with missing data). The sensitivities of the protocols were 86.6% for IRT/IRT, 89.9% for IRT/p.F508del, and 95.8% for IRT/12 mutations. Including 12 mutations in the analysis detected one patient who would otherwise have been missed and, had this protocol been implemented from 1989, it would have detected four others.
CONCLUSION: Most babies with CF without meconium ileus, a family history or antenatal diagnosis are detected by newborn screening. Despite improved sensitivity with the 12-mutation analysis, most infants detected would have been diagnosed using the IRT/p.F508del protocol.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22256939     DOI: 10.5694/mja11.10686

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  13 in total

1.  Molecular testing for cystic fibrosis carrier status practice guidelines: recommendations of the National Society of Genetic Counselors.

Authors:  Elinor Langfelder-Schwind; Barbara Karczeski; Michelle N Strecker; Joy Redman; Elaine A Sugarman; Christina Zaleski; Trisha Brown; Steven Keiles; Amy Powers; Sumheda Ghate; Rebecca Darrah
Journal:  J Genet Couns       Date:  2013-09-07       Impact factor: 2.537

2.  Australasian Guideline (2nd Edition): an Annex to the CLSI and UK Guidelines for the Performance of the Sweat Test for the Diagnosis of Cystic Fibrosis.

Authors:  John Massie; Ronda Greaves; Michael Metz; Veronica Wiley; Peter Graham; Samantha Shepherd; Richard Mackay
Journal:  Clin Biochem Rev       Date:  2017-11

3.  PATHOPHYSIOLOGIC EVALUATION OF THE TRANSGENIC CFTR "GUT-CORRECTED" PORCINE MODEL OF CYSTIC FIBROSIS.

Authors:  Stephen T Ballard; Jessica W Evans; Holly S Drag; Michele Schuler
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-08-19       Impact factor: 5.464

4.  Screening for Regulatory Variants in 460 kb Encompassing the CFTR Locus in Cystic Fibrosis Patients.

Authors:  Jenny L Kerschner; Sujana Ghosh; Alekh Paranjapye; Wilmel R Cosme; Marie-Pierre Audrézet; Miyuki Nakakuki; Hiroshi Ishiguro; Claude Férec; Johanna Rommens; Ann Harris
Journal:  J Mol Diagn       Date:  2018-10-05       Impact factor: 5.568

5.  The improvement of the best practice guidelines for preimplantation genetic diagnosis of cystic fibrosis: toward an international consensus.

Authors:  Anne Girardet; Victoria Viart; Stéphanie Plaza; Gemma Daina; Martine De Rycke; Marie Des Georges; Francesco Fiorentino; Gary Harton; Aliya Ishmukhametova; Joaquima Navarro; Caroline Raynal; Pamela Renwick; Florielle Saguet; Martin Schwarz; Sioban SenGupta; Maria Tzetis; Anne-Françoise Roux; Mireille Claustres
Journal:  Eur J Hum Genet       Date:  2015-05-27       Impact factor: 4.246

6.  High-resolution computed tomography findings in young infants with cystic fibrosis detected by newborn screening.

Authors:  Renata Wrobel Folescu Cohen; Tânia Wrobel Folescu; Marcia Cristina Bastos Boechat; Vania Matos Fonseca; Elizabeth Andrade Marques; Robson Souza Leão
Journal:  Clinics (Sao Paulo)       Date:  2019-10-21       Impact factor: 2.365

7.  Comprehensive CFTR gene analysis of the French cystic fibrosis screened newborn cohort: implications for diagnosis, genetic counseling, and mutation-specific therapy.

Authors:  Marie Pierre Audrézet; Anne Munck; Virginie Scotet; Mireille Claustres; Michel Roussey; Dominique Delmas; Claude Férec; Marie Desgeorges
Journal:  Genet Med       Date:  2014-08-14       Impact factor: 8.822

8.  Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene.

Authors:  Patrick R Sosnay; Karen R Siklosi; Fredrick Van Goor; Kyle Kaniecki; Haihui Yu; Neeraj Sharma; Anabela S Ramalho; Margarida D Amaral; Ruslan Dorfman; Julian Zielenski; David L Masica; Rachel Karchin; Linda Millen; Philip J Thomas; George P Patrinos; Mary Corey; Michelle H Lewis; Johanna M Rommens; Carlo Castellani; Christopher M Penland; Garry R Cutting
Journal:  Nat Genet       Date:  2013-08-25       Impact factor: 38.330

9.  Early diagnosis from newborn screening maximises survival in severe cystic fibrosis.

Authors:  Gloria Tridello; Carlo Castellani; Ilaria Meneghelli; Anna Tamanini; Baroukh M Assael
Journal:  ERJ Open Res       Date:  2018-04-20

Review 10.  The Changing Epidemiology of Cystic Fibrosis: Incidence, Survival and Impact of the CFTR Gene Discovery.

Authors:  Virginie Scotet; Carine L'Hostis; Claude Férec
Journal:  Genes (Basel)       Date:  2020-05-26       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.